Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
InChI
InChIKey=XWALNWXLMVGSFR-HLXURNFRSA-N
InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.steroidal.com/steroid-profiles/dianabol/Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Sources: https://www.steroidal.com/steroid-profiles/dianabol/
Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Metandienone is an orally active synthetic anabolic-androgenic steroid. In 1970, the FDA accepted that Metandienone (Dianabol) was “Probably Effective” in treating post-menopausal osteoporosis and pituitary-deficient dwarfism. Methandrostenolone is still produced today, but typically in nations with loose prescription drug regulations and by companies that still prefer to cater to an underground athletic market. Androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
|||
Target ID: CHEMBL3859 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
|||
Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years |
Disc. AE: Infertility... AEs leading to discontinuation/dose reduction: Infertility (15 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Infertility | 15 patients Disc. AE |
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years |
PubMed
Title | Date | PubMed |
---|---|---|
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. | 1972 Dec 16 |
|
Experimental progressive muscular dystrophy and its treatment with high doses anabolizing agents. | 1978 Apr |
|
Hypoplastic anemia associated with metolazone. | 1979 Jul 13 |
|
Bleeding oesophageal varices associated with anabolic steroid use in an athlete. | 1990 Oct |
|
Practical uses for ecdysteroids in mammals including humans: an update. | 2003 |
|
[Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage]. | 2003 |
|
Myocardial infarction with intracoronary thrombus induced by anabolic steroids. | 2004 Dec |
|
Screening of anabolic steroids in horse urine by liquid chromatography-tandem mass spectrometry. | 2005 Apr 29 |
|
Detection, quantification and confirmation of anabolic steroids in equine plasma by liquid chromatography and tandem mass spectrometry. | 2005 Dec 27 |
|
Validation of a GC-MS screening method for anabolizing agents in aqueous nutritional supplements. | 2005 Jan |
|
Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. | 2005 May |
|
Separation and online preconcentration by multistep stacking with large-volume injection of anabolic steroids by capillary electrokinetic chromatography using charged cyclodextrins and UV-absorption detection. | 2005 Nov |
|
Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry. | 2006 Apr |
|
Research of stimulants and anabolic steroids in dietary supplements. | 2006 Feb |
|
Doping control for metandienone using hair analyzed by gas chromatography-tandem mass spectrometry. | 2006 May 19 |
|
High amounts of 17-methylated anabolic-androgenic steroids in effervescent tablets on the dietary supplement market. | 2007 Feb |
|
[Main symptom jaundice--differential diagnosis at the bedside]. | 2007 Jan 15 |
|
A downscaled multi-residue strategy for detection of anabolic steroids in bovine urine using gas chromatography tandem mass spectrometry (GC-MS3). | 2007 Mar 14 |
|
Anabolic steroid abuse among teenage girls: an illusory problem? | 2007 May 11 |
|
The dire consequences of doping. | 2008 Aug 23 |
|
Detection of urinary metabolites common to structurally related 17alpha-alkyl anabolic steroids in horses and application to doping tests in racehorses: methandienone, methandriol, and oxymetholone. | 2008 Jun |
|
[Conversion of 17 alpha-methyltestosterone to methandrostenolone by the bacterium Pimelobacter simplex VKPM Ac-1632 with the presence of cyclodextrins]. | 2008 Nov-Dec |
|
A new mixed micellar electrokinetic chromatography method for analysis of natural and synthetic anabolic steroids. | 2009 Jan 15 |
|
Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism. | 2009 Nov |
|
Steroid metabolism in chimeric mice with humanized liver. | 2009 Nov |
|
Humanized animal models to study drug metabolism: no longer a "chimera"? | 2009 Oct |
|
Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids. | 2010 Apr |
|
Feasibility of capillary liquid chromatography/microchip atmospheric pressure photoionization mass spectrometry in analyzing anabolic steroids in urine samples. | 2010 Apr 15 |
|
Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse. | 2010 Nov |
|
The anabolic steroid methandienone targets the hypothalamic-pituitary-testicular axis and myostatin signaling in a rat training model. | 2012 Jan |
|
Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - insights from metandienone metabolism. | 2012 Sep 18 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23675320
Cell death was evaluated by staining PC12 cells treated for 48 h with 75 uM methandienone. Methandienone is toxic to neurons, inducing death in treated cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:27 GMT 2025
by
admin
on
Mon Mar 31 17:33:27 GMT 2025
|
Record UNII |
COZ1R7EOCC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA14AA03
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WHO-ATC |
A14AA03
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WHO-ATC |
D11AE01
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
LIVERTOX |
613
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WIKIPEDIA |
Designer-drugs-Methandrostenolone
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
||
|
WHO-VATC |
QD11AE01
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1734
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
72-63-9
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
3360
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL1418176
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
COZ1R7EOCC
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
METHANDROSTENOLONE
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
D008696
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
100000089098
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
983
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
m7293
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB13586
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
C87589
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
DTXSID2023276
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
SUB08812MIG
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
6300
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
42722
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | |||
|
6818
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
200-787-2
Created by
admin on Mon Mar 31 17:33:27 GMT 2025 , Edited by admin on Mon Mar 31 17:33:27 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |